Text this: Cost-utility and budget impact analyses of gefitinib in second-line treatment for advanced non-small cell lung cancer from Thai payer perspective

  ______    _____    _____      ______   _    _   
 /_   _//  |  ___|| |  __ \\   /_   _// | || | || 
 `-| |,-   | ||__   | |  \ ||   -| ||-  | || | || 
   | ||    | ||__   | |__/ ||   _| ||_  | \\_/ || 
   |_||    |_____|| |_____//   /_____//  \____//  
   `-`'    `-----`   -----`    `-----`    `---`